ClinicalTrials.gg
Active, not recruitingNCT06293456Updated Sep 8, 2026

Study of Poetic Dignity Therapy for Sexual and Gender Minority Patients With Cancer

An interventional study of Dignity Therapy in End of Life, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Death with a site in United States — 13 open to participants now, 27 under way, 1 of them phase 3. Death · United States.

Enrollment
71st of 79
15 · median 154
Started
2024
with 8 others
No phase
68 of 118
9 open now
Primary completion
2027-01
later than 11 of 26 live
Registered
103rd of 118
by date

Among the 118 studies in Death with a site in United States, this one is the 71st largest by enrollment of the 79 interventional ones that give a count, is one of 9 that started in 2024, is one of 68 with no phase, reaches primary completion later than 11 of the 26 other live ones, and was the 103rd registered.

Death

457 studies on the registry are indexed under Death; 85 are open to participants now.

Browse Death studies →

Open to participants now

13 of the 118 studies in Death with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Death with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out if dignity therapy is practical and works well for sexual and gender minority (SGM) patients in MSK. SGM includes, but is not limited to, people who identify as lesbian, gay, bisexual, transgender, and/or queer/questioning (LGBTQ+). Dignity therapy is a type of psychotherapy where the clinician asks the patient questions to allow the patient to express their individual life story and ultimately be able to create a legacy document of their experiences that can be shared with their loved ones.

03

Conditions studied

  • End of Life

Browse trials for

Keywords

  • Dignity Therapy (DT)
  • End of Life (EOL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SGM (as per self-report) palliative care patients identified through Memorial Sloan Kettering Cancer Center's Palliative Care team and primary solid tumor oncology clinics.
  • Age 18 and older (as per self-report/EHR)
  • English-speaking as per the English language assessment items below and wil ing to receive the intervention in English.

    o What is the participant's preferred language?

  • (Specify Lang)___________________________

    • How well does the participant speak English?
    • Very well (PARTICIPANT IS ELIGIBLE)
    • Well (PARTICIPANT is ELIGIBLE)
    • Not well (PARTICIPANT is NOT ELIGIBLE)
    • Not at all (PARTICIPANT is NOT ELIGIBLE)

Exclusion criteria

Exclusion Criteria:

  • Delirium/ altered mental status prohibitive of providing consent.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Dignity Therapy

    The DT intervention is a 45-75-minute virtual interview, which is recorded and transcribed within 1-2 weeks of the interview.

    Other: Dignity Therapy

Interventions

  • OtherDignity Therapy

    A trained research staff member will conduct the DT interview virtually. The interview will occur or by phone only if the participant lacks access to technology for videoconferencing. The interviewer asks a series of open-ended questions that encourages patients to talk about their lives and what matters most to them.

06

What researchers measure

Primary outcomes

  1. the number of patients who complete the intervention

    This requires meeting both of the following criteria: i) collection of the DT Interview for 30 patients; and ii) delivery of the poem to at least 22 (\>75%) participants.

    Time frame: 1 year

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 107 non-industry interventional studies with no phase under Death, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 111 studies reached it within 23 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 5, 2024
StartActual
Jan 29, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06293456
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Jan 29, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

William E Rosa, Ph.D., MBE, NP
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion